Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PathChooser

Financiado

Cerrado

Innovative mechanistic based strategies for delivery of therapeutic macromolecu...

Innovative mechanistic based strategies for delivery of therapeutic macromolecules across cellular and biological barriers Nanomedicine offers capability to significantly change the course of treatment for life-threatening diseases. Many of the most significant current therapeutic targets, to be viable in practice, require the efficient crossing of at... ver más

30/09/2017

NUID UCD

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-09-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

NUID UCD

0.00€ | Lider

EPOS IASIS

N.D. | Participante

MPG

N.D. | Participante

ACS

N.D. | Participante

Proyectos interesantes

BIO2013-41019-P

Nanotechnology

Medical Technol...

151K€ Cerrado

EUIN2013-51165

Nanotechnology

Medical Technol...

11K€ Cerrado

BIOINOHYB

Nanotechnology

Medical Technol...

2M€ Cerrado

NABBA

Nanotechnology

Medical Technol...

3M€ Cerrado

PRE2020-095972

Nanotechnology

Medical Technol...

99K€ Cerrado

PCI2019-103715

Nanotechnology

Medical Technol...

59K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Nanomedicine offers capability to significantly change the course of treatment for life-threatening diseases. Many of the most significant current therapeutic targets, to be viable in practice, require the efficient crossing of at least one biological barrier. However, the efficient and controlled crossing of the undamaged barrier is difficult. The range of small molecules that can successfully do so (via diffusive or other non-specific processes) is limited in size and physiochemical properties, greatly restricting the therapeutic strategies that may be applied. In practice, after several decades of limited success, there is a broad consensus that new multi-disciplinary, multi-sectoral strategies are required. Key needs include detailed design and understanding of the bionano-interafce, re-assessment of in vitro models used to assess transport across barriers, and building regulatory considerations into the design phase of nanocarriers. The overarching premises of the PathChooser ITN are that (i) significant advances can only be made by a more detailed mechanistic understanding of key fundamental endocytotic, transcytotic, and other cellular processes, especially biological barrier crossing; (ii) elucidating the Mode of Action / mechanism of successful delivery systems (beyond current level) will ensure more rapid regulatory and general acceptance of such medicines. Paramount in this is the design and characterization of the in situ interface between the carrier system and the uptake and signalling machinery. (iii) inter-disciplinary knowledge from a range of scientific disciplines is required to launch a genuine attack on the therapeutic challenge. The PathChooser ITN program of research and training will equip the next generation of translational scientists with the tools to develop therapies for a range of currently intractable (e.g. hidden in the brain) and economically unviable diseases (e.g. orphan diseases affecting a limited population).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores